WallStSmart

Cytek Biosciences Inc (CTKB)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 10175% more annual revenue ($20.98B vs $204.17M). GEHC leads profitability with a 9.1% profit margin vs -36.2%. GEHC earns a higher WallStSmart Score of 57/100 (C).

CTKB

Hold

41

out of 100

Grade: D

Growth: 7.3Profit: 2.0Value: 6.7Quality: 8.5
Piotroski: 4/9Altman Z: 2.45

GEHC

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 5.7Quality: 4.5
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CTKBUndervalued (+42.8%)

Margin of Safety

+42.8%

Fair Value

$7.62

Current Price

$4.09

$3.53 discount

UndervaluedFair: $7.62Overvalued

Intrinsic value data unavailable for GEHC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CTKB3 strengths · Avg: 9.0/10
EPS GrowthGrowth
73.5%10/10

Earnings expanding 73.5% YoY

Debt/EquityHealth
0.119/10

Conservative balance sheet, low leverage

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

GEHC2 strengths · Avg: 8.0/10
P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Areas to Watch

CTKB4 concerns · Avg: 2.0/10
Market CapQuality
$559.19M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-22.6%2/10

ROE of -22.6% — below average capital efficiency

Free Cash FlowQuality
$-4.90M2/10

Negative free cash flow — burning cash

Profit MarginProfitability
-36.2%1/10

Currently unprofitable

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.844/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-30.9%2/10

Earnings declined 30.9%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CTKB

The strongest argument for CTKB centers on EPS Growth, Debt/Equity, Price/Book.

Bull Case : GEHC

The strongest argument for GEHC centers on P/E Ratio, Price/Book.

Bear Case : CTKB

The primary concerns for CTKB are Market Cap, Return on Equity, Free Cash Flow.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

CTKB profiles as a turnaround stock while GEHC is a value play — different risk/reward profiles.

CTKB carries more volatility with a beta of 1.19 — expect wider price swings.

GEHC is growing revenue faster at 7.4% — sustainability is the question.

GEHC generates stronger free cash flow (112M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (57/100 vs 41/100). CTKB offers better value entry with a 42.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cytek Biosciences Inc

HEALTHCARE · MEDICAL DEVICES · USA

Cytek Biosciences Inc (CTKB) is at the forefront of multi-parameter flow cytometry, offering advanced cell analysis solutions that drive innovation in the life sciences industry. The company's proprietary technologies play a critical role in pivotal research fields such as immunology, cancer diagnostics, and drug development, addressing the growing demand for high-precision cellular analysis. Cytek’s dedication to innovation, coupled with its robust customer support, positions it as a significant player within the biotechnology sector. With a comprehensive product range and a solid market footprint, Cytek is well-equipped to facilitate groundbreaking discoveries that can dramatically enhance healthcare outcomes.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?